Ten of the 29 directors of California's new stem cell program serve on biotech or pharmaceutical firms' boards of directors or have extensive holdings in those industries, leading critics to challenge their ability to fairly represent taxpayers in doling out $3 billion in state funds. Members of the Independent Citizens Oversight Committee, created by voter passage of the stem cell initiative in November, reported interests ranging from real estate to movie production in statements of economic interest filed this week. Six members, including Sacramento physician Francisco Prieto and University of California, Davis, medical school head Claire Pomeroy, had no reportable...